FY2025 EPS Estimates for 89bio Lifted by Cantor Fitzgerald

89bio, Inc. (NASDAQ:ETNB) – Research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for 89bio in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($1.88) per share for the year, up from their previous forecast of ($2.44). Cantor Fitzgerald has a “Overweight” rating and a $29.00 price objective on the stock. The consensus estimate for 89bio’s current full-year earnings is ($3.19) per share.

89bio (NASDAQ:ETNB) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.42).

A number of other research firms also recently commented on ETNB. HC Wainwright restated a “buy” rating and set a $21.00 price objective (down from $29.00) on shares of 89bio in a report on Friday, February 28th. UBS Group boosted their target price on shares of 89bio from $25.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Wolfe Research started coverage on 89bio in a research note on Tuesday, February 4th. They set an “outperform” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of 89bio in a research note on Wednesday, February 19th. Finally, Raymond James raised 89bio to a “strong-buy” rating in a research report on Thursday, December 12th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $30.29.

89bio Trading Up 1.9 %

Shares of ETNB opened at $8.64 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.66 and a quick ratio of 11.66. The stock has a market cap of $916.93 million, a price-to-earnings ratio of -2.97 and a beta of 1.17. 89bio has a 1-year low of $5.99 and a 1-year high of $13.71. The firm has a 50 day simple moving average of $8.79 and a 200-day simple moving average of $8.48.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ETNB. Federated Hermes Inc. grew its position in 89bio by 206.9% during the fourth quarter. Federated Hermes Inc. now owns 6,283 shares of the company’s stock valued at $49,000 after purchasing an additional 4,236 shares in the last quarter. Quarry LP acquired a new position in 89bio during the fourth quarter valued at approximately $55,000. Kingswood Wealth Advisors LLC acquired a new stake in shares of 89bio in the fourth quarter valued at about $86,000. Sandia Investment Management LP lifted its holdings in shares of 89bio by 28.5% during the fourth quarter. Sandia Investment Management LP now owns 11,286 shares of the company’s stock worth $88,000 after buying an additional 2,500 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new stake in 89bio in the 4th quarter valued at $87,000.

Insider Buying and Selling

In related news, insider Quoc Le-Nguyen sold 10,963 shares of 89bio stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $6.49, for a total value of $71,149.87. Following the sale, the insider now directly owns 271,833 shares in the company, valued at $1,764,196.17. This trade represents a 3.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Charles Mcwherter purchased 5,000 shares of 89bio stock in a transaction on Tuesday, January 21st. The shares were acquired at an average price of $6.55 per share, with a total value of $32,750.00. Following the transaction, the director now directly owns 15,000 shares in the company, valued at $98,250. This trade represents a 50.00 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 5,724,285 shares of company stock valued at $50,072,194. Insiders own 2.80% of the company’s stock.

89bio Company Profile

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.